"One deal next year": Lee Seung-ju, CEO of Orum Therapeutics, what's his next move? [Bio Figures in Focus]
Predicted impact: Low
CEO interview on future deal goals; vague with no specific deal size disclosed.
Orum Therapeutics오름테라퓨틱
475830 · KOSDAQ · ₩475830 · 오름테라퓨틱
₩16,070▼ ₩40 (0.25%)End-of-day · Oct 27, 2026 · End-of-day prices.
Oryn Therapeutics CEO Lee Seung-joo buys ₩170M worth of treasury shares as stock falls
Predicted impact: Low
CEO buys ₩170M of treasury shares, small versus ₩353B market value.
Orum Therapeutics begins first patient dosing in Phase 1 trial of blood cancer treatment 'ORM-1153'
Predicted impact: Low· Actual: −11.2% vs sector, volume 0.3× normal (5 trading days)
Phase 1 first patient dosing; early-stage clinical step with no near-term revenue size.
Also known as: Orum Therapeutics / 오름테라퓨틱 / 475830 / KRX:475830
Source: KRX statistical information